HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Creates Import Alert For Ayurvedic Supplements Linked To High Lead, Mercury Levels

This article was originally published in The Tan Sheet

Executive Summary

FDA creates an alert identifying only products made by Shree Baidyanath Ayurved Bhawan Pvt. at three manufacturing sites. The agency in January also updates around 75 alerts to seize imports of kratom-containing supplements.

You may also be interested in...



Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.

Supplement Industry Oversight Among FDA Programs Targeted For $86M Budget Cut

The first budget proposal by President Trump suggests research by FDA's National Center for Toxicological Research on food- and nutritional supplement-related issues will be curtailed as part of a $3m cut to the center's appropriation.

FTC Health Claims Guidance ‘Lacks Legal Basis,’ Conflicts With FDA’s Supplement Regulations – CRN

“There is no bright-line requirement that a company possess randomized, controlled clinical studies before making so-called ‘health benefit’ claims for dietary supplements,” CRN states in petition. FTC, however, says it “makes no bright-line distinctions between categories of health-related products or claims.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel